comparemela.com

Pharma Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FOR THE SECOND CONSECUTIVE YEAR COYNE PUBLIC RELATIONS IS NOMINATED FOR THE BEST HEALTHCARE PRACTICE IN THE COUNTRY

Agency receives three additional nominations for the PRWeek U.S. Healthcare + Pharma Communications AwardsPARSIPPANY, N.J., April 20, 2023 /PRNews.

New jerseyUnited statesNew yorkKelly denckerLisa wolleonWorldcom public relations groupPacira biosciences incHaymarket media incPharma communicationsCoyne public relationsU haymarket media groupOutstanding agency practiceHealthcare conferencePacira biosciencesThese awardsExecutive vice president

Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, in idiopat.

Rheinland pfalzKerry wycisloLos angelesToby maherBoehringer ingelheim pharmaceuticals incHuman pharma communicationsAnimal healthBoehringer ingelheimKeck school of medicineDrug administrationCorporate affairsOrphan drug designationClinical medicineKeck schoolBreakthrough therapyOrphan drug designations

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at.

United statesComunidad autonoma de catalunaKerry wycisloRobin deterdingBoehringer ingelheimSusanne stowasserBoehringer ingelheim pharmaceuticalsBoehringer ingelheim pharmaceuticals incEuropean respiratory society international congressDrug administrationInternational congressEuropean respiratory societyHuman pharma communicationsAnimal healthEuropean medicines agencyCorporate affairs

Boehringer Ingelheim s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

/PRNewswire/ Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was.

Rheinland pfalzUnited statesSan franciscoSusan holzCarinne brouillonLuca richeldiBoehringer ingelheim pharmaceuticalsBoehringer ingelheim pharmaceuticals incBoehringer ingelheimDrug administrationHuman pharma communicationsAnimal healthInternational conference breaking newsCorporate affairsAmerican thoracic societyNew england journal

Boehringer Ingelheim s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

/PRNewswire/ Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was.

Rheinland pfalzUnited statesSan franciscoSusan holzCarinne brouillonLuca richeldiBoehringer ingelheim pharmaceuticalsBoehringer ingelheim pharmaceuticals incBoehringer ingelheimDrug administrationHuman pharma communicationsAnimal healthInternational conference breaking newsCorporate affairsAmerican thoracic societyNew england journal

vimarsana © 2020. All Rights Reserved.